Sign In
Buy AIM
$0.732
-0.0947 (-11.46%)
At Close: Jun 03, 2026
Why Is United Airlines Down By Over 6%? Here Are 25 Stocks Moving In Thursday's Pre-Market Session
09:53am, Thursday, 21'st Jul 2022 Benzinga
Gainers
Tuesday Morning Corporation (NASDAQ: TUEM) rose 72.1% to $0.3420 in pre-market trading after dipping 30% on Wednesday. Tuesday Morning recently announced partnership with Intalytics for custo
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data
12:05pm, Wednesday, 20'th Jul 2022 GlobeNewswire Inc.
Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC)
AIM ImmunoTech宣布最近从Jorgl活动团体收到的董事提名无效
04:55pm, Monday, 18'th Jul 2022 GlobeNewswire Inc.
向联邦法院提起诉讼，以迫使活动团体透露真实意图（包括对公司的潜在敌意收购）并防止该团体继续违反联邦证券法以及美国证券交易委员会（SEC）�
AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series
12:05pm, Thursday, 14'th Jul 2022 GlobeNewswire Inc.
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July
AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series
08:05am, Thursday, 14'th Jul 2022
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July
This Healthcare Stock is Surging By Over 21%: Here's 24 Biggest Movers In Tuesday's Pre-Market
10:14am, Tuesday, 12'th Jul 2022 Benzinga
Gainers
Versus Systems Inc. (NASDAQ: VS) rose 66% to $0.7802 in pre-market trading. Versus Systems, last month, received NASDAQ notification regarding minimum bid price deficiency.
Histogen Inc.. (NA
Aspen Aerogels And 28 Stocks Moving Premarket
10:33am, Thursday, 30'th Jun 2022 Benzinga
Gainers
Revelation Biosciences, Inc. (NASDAQ: REVB) rose 149.3% to $1.56 in pre-market trading after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phas
LiveOne And 24 Stocks Moving Premarket
10:32am, Wednesday, 29'th Jun 2022 Benzinga
Gainers
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 92.9% to $0.2295 in pre-market trading. Allena Pharmaceuticals said it previously entered into at market issuance sales agreement with B. Ril
Why Is Kezar Life Sciences Surging By 78%? 25 Stocks Moving In Tuesday's Pre-Market Session
11:00am, Tuesday, 28'th Jun 2022 Benzinga
Gainers
Kezar Life Sciences, Inc. (NASDAQ: KZR) rose 78% to $10.29 in pre-market trading after the company reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomi
AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing
12:35pm, Tuesday, 21'st Jun 2022 GlobeNewswire Inc.
Company enters into a lease agreement with the state-supported New Jersey Bioscience Center at North Brunswick, one of the nation’s leading business incubators dedicated to life sciences and biotech
AIM ImmunoTech inks lease deal for new state-of-the-art product development and testing facility in New Jersey
09:56am, Tuesday, 21'st Jun 2022
AIM ImmunoTech Inc (NYSE:AIM) announced that it has entered into a lease agreement with the New Jersey Economic Development Authority for a 5,210 square foot research and development (R&D) facility at
AIM ImmunoTech凭借荷兰实用新型专利的颁发巩固Ampligen®的知识产权组合。这些专利涵盖Ampligen®及其他AIM开发的用于COVID-19治疗或预防的dsRNA产品
01:36am, Tuesday, 14'th Jun 2022 GlobeNewswire Inc.
专利组合的进一步扩大支持了公司在荷兰的各种Ampligen研究项目，这些项目研究多种类型的癌症和病毒疾病，包括COVID-19 专利组合的进一步扩大支持了公
AIM ImmunoTech versterkt intellectuele eigendomsportefeuille voor Ampligen® met de uitgifte van een nieuw Nederlands octrooi dat Ampligen® en andere door AIM ontwikkelde dsRNA-producten bestrijkt voor gebruik bij de behandeling of preventie van COVID-19
01:36am, Tuesday, 14'th Jun 2022 GlobeNewswire Inc.
Verdere uitbreiding van de octrooiportefeuille ondersteunt het uitgebreide Ampligen-onderzoeksprogramma van het bedrijf voor meerdere soorten kankers en virusziekten, waaronder COVID-19 in Nederland V
Further expansion of patent portfolio supports of the Company’s extensive Ampligen research program across multiple types of cancers and viral diseases, including COVID-19 in the Netherlands Further
AIM ImmunoTech Inc (NYSE:AIM) revealed that the Netherlands Patent Office (Octrooicentrum Nederland) has issued Patent No 2027383 - a utility patent - covering Ampligen (rintatolimod) and other dsRNA
